Abstract: A monoclonal antibody which reacts with glycolipid asialo GM1 but not with any of glycolipids GM1 and GM2 can be produced by hybridoma cells obtained by fusing antibody-producing cells of a mammal immunized with the glycolipid asialo GM1 with myeloma cells.

Abstract: The invention relates to antibodies which immunologically bind epitopes present on B cell-bound but not secreted IgA. This is accomplished by targeting extracellular epitopes on the membrane anchoring peptide of the .alpha. chain which form, entirely or in part, antigenic epitopes unique to membrane-bound but not secreted IgA.

Abstract: The present invention discloses a novel cell surface marker and antigenic portions thereof; antibodies reactive with said marker; polynucleotides encoding said marker and antigenic portions thereof; methods of diagnosis and treatment using said polynucleotides and antibodies.

Abstract: The invention is directed to the human hybridoma designated MCA 86 and having A.T.C.C. Accession No. HB 9669 and human monoclonal antibodies produced by hybridoma MCA 86. Human monoclonal antibodies produced by hybridoma MCA 86 immunologically binds to both gp41 and gp120 envelope glycoproteins of Human Immunodeficiency Virus (HIV). These monoclonal antibodies are useful in the diagnosis of HIV infection.

Abstract: Monoclonal antibodies are provided which differentiate between native and modified sequence proteins. Also provided are methods for using monoclonal antibodies to determine the relative amount of native and modified sequence proteins in a sample.

Abstract: The present invention provides (1) an antibody which (a) specifically binds to human TGF-.beta.3 and (b) exhibits substantially no cross reactivity with TGF-.beta.1 or TGF-.beta.2 and (2) antibodies directed against the pro region of the TGF-.beta. precursor. Further, this invention provides a pharmaceutical composition comprising the pro region of the TGF-.beta. precursor. Also, this invention provides methods for diagnosing, detecting and treating subjects suffering from disorders associated with TGF-.beta.3.

Abstract: The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody, to genetic sequences coding therefor, and to recombinant DNA methods of producing such molecule and uses for such molecule.

Abstract: Disclosed are a family of synthetic proteins having binding affinity for a preselected antigen, and multifunctional proteins having such affinity. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS) The sites comprise V.sub.H -V.sub.L or V.sub.L -V.sub.H -like single chains wherein the V.sub.H and V.sub.L -like sequences are attached by a polypeptide linker, or individual V.sub.H or V.sub.L -like domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function, e.g., as an enzyme, toxin, binding site, or site for attachment to an immobilization media or radioactive atom.

Abstract: Disclosed is a method for the in vivo lysis of a thrombus in a host by administration of a conjugate consisting of a monoclonal antibody specific for fibrin coupled to a plasminogen activator such as tissue plasminogen activator, urokinase or streptokinase.

Abstract: Antibody defining structure present in fibronectins from tumors and fetal tissues but absent in fibronectins from normal adult tissues and plasma; useful for diagnosing and treating human cancers.

Abstract: B-cell lymphomas express surface immunoglobulin (immunoglobulin) containing unique idiotypic (idiotype) determinants which may be exploited as tumor specific markers. The inventor has produced murine monoclonal antibodies (MAbs) reactive with the idiotype marker derived from 67 patients with low grade, follicular, small cleaved cell lymphoma. Out of 199 monoclonal antibodies, 47 (24%) were found to react with pooled normal human serum immunoglobulin in concentrations ranging from 0.6 .mu.g/ml to 160 .mu.g/ml. Of these 40 monoclonal antibodies, 90% cross-reacted with idiotype present in normal serum in levels <50 .mu.g/ml. Thirty-two of these anti-idiotypes were directed against a shared idiotope expressed on another patient's lymphoma cells. The frequency of shared idiotope expression defined by each antibody ranged from 0.26% to 3.9% of the B-cell lymphomas tested. A panel of five anti-idiotype antibodies reacted with 80% of AIDS associated lymphomas.

Abstract: High-affinity murine monoclonal antibodies to t-PA were prepared which prolong the in vivo functional half-life of t-PA without decreasing its plasminogen-activator activity.

Abstract: An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using recombinant DNA techniques. The gene coding sequences for producing the altered antibody may be produced by site-directed mutagenesis using long oligonucleotides.

Abstract: The present invention provides an altered antibody molecule wherein a residue in a surface pocket on the molecule has been changed to a cysteine residue to introduce a thiol group in the surface pocket and a process for its production by recombinant DNA technology.

Abstract: Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 antibodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passave vaccination procedures.

Abstract: The present invention contemplates glycopolypeptide multimers having a polypeptide that contain an immunoglobulin amino acid residue sequence and an oligosaccharide that comprises a core pentasaccharide and N-acetylglucosamine-containing outer branches, such that the multimer is free from sialic acid. The production of passive immunity in an animal by administering a sialic acid free glycopolypeptide multimer is also contemplated. In addition, the invention describes a method for producing a glycopolypeptide multimer by introducing first and second mammalian genes encoding the constituent parts of the multimer into first and second respective members of a plant species, generating a progeny from the first and second plant species members, and isolating the glycopolypeptide multimer from the progeny plant.

Abstract: Specific, selective inhibitors of catalytic antibodies both synthetic and naturally occurring, their use and compositions thereof are disclosed. In particular, an inhibitor preventing the hydrolysis of the peptide bond between amino acid residues 16 and 17 in the neurotransmitter vasoactive intestinal peptide (VIP) by an anti-VIP catalytic autoantibody is disclosed.

Abstract: The present invention relates to the monoclonal antibody (termed D612) having selective reactivity for gastrointestinal carcinoma and methods for employing the same. A hybridoma producing such antibodies has been prepared.

Abstract: The present invention provides an envelope glycoprotein which is encoded by an early structural gene of human cytomegalovirus, and polyclonal and monoclonal antibodies to the early envelope glycoprotein.

Abstract: A method is disclosed for the treatment and prevention of graft versus host disease in man through the combined use of anti-CD8 monoclonal antibodies and a CD4.sup.+ cell inactivator.